These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 35894128)

  • 21. Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2.
    Li C; Zhou H; Guo L; Xie D; He H; Zhang H; Liu Y; Peng L; Zheng L; Lu W; Mei Y; Liu Z; Huang J; Wang M; Shu D; Ding L; Lang Y; Luo F; Wang J; Huang B; Huang P; Gao S; Chen J; Qian CN
    J Transl Med; 2022 Jul; 20(1):314. PubMed ID: 35836239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
    Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
    J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
    Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
    Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corilagin and 1,3,6-Tri-
    Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
    Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant.
    Sevenich M; van den Heuvel J; Gering I; Mohrlüder J; Willbold D
    J Virol; 2022 Jul; 96(13):e0068522. PubMed ID: 35674432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex.
    Jaiswal G; Yaduvanshi S; Kumar V
    J Biomol Struct Dyn; 2022 Sep; 40(14):6671-6681. PubMed ID: 33645443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
    Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
    J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.
    Di Paola L; Hadi-Alijanvand H; Song X; Hu G; Giuliani A
    J Proteome Res; 2020 Nov; 19(11):4576-4586. PubMed ID: 32551648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2.
    Lee RK; Li TN; Chang SY; Chao TL; Kuo CH; Pan MY; Chiou YT; Liao KJ; Yang Y; Wu YH; Huang CH; Juan HF; Hsieh HP; Wang LH
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
    Larue RC; Xing E; Kenney AD; Zhang Y; Tuazon JA; Li J; Yount JS; Li PK; Sharma A
    Bioconjug Chem; 2021 Jan; 32(1):215-223. PubMed ID: 33356169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.
    Hou Y; Ge S; Li X; Wang C; He H; He L
    Chem Biol Interact; 2021 Apr; 338():109420. PubMed ID: 33609497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-Throughput Assay for Identifying Diverse Antagonists of the Binding Interaction between the ACE2 Receptor and the Dynamic Spike Proteins of SARS-CoV-2.
    Sammons RM; Bohanon AL; Kowtha A; Dejong A; Cho EJ; Kaoud TS; Dalby KN
    ACS Infect Dis; 2022 Nov; 8(11):2259-2270. PubMed ID: 36315931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
    Basu A; Sarkar A; Maulik U
    Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential use of the S-protein-Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019.
    Feng L; Fu S; Zhang P; Zhang Y; Zhao Y; Yao Y; Luo L; Ping P
    Front Public Health; 2022; 10():1050034. PubMed ID: 36518573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner.
    Isobe A; Arai Y; Kuroda D; Okumura N; Ono T; Ushiba S; Nakakita SI; Daidoji T; Suzuki Y; Nakaya T; Matsumoto K; Watanabe Y
    Commun Biol; 2022 Nov; 5(1):1188. PubMed ID: 36335195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
    Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
    J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
    Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
    PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.